p16(INK4) and p15(INK4B) alterations in primary gynecologic malignancy

Gynecologic Oncology

Volumn 65, Issue 2, 1997, Pages 319-324

  Wong, Y F ^a   Chung, T K H ^a   Cheung, T H ^a   Nobori, T ^b   Yim, S F ^a   Lai, K W H ^a   Yu, A L ^c   Diccianni, M B ^c   Li, T Z ^d   Chang, A M Z ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 9; FEMALE; GENE DELETION; GENE MAPPING; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; FEMALE GENITAL TRACT TUMOR; GENETICS; MUTATION; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

CARRIER PROTEIN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; GENITAL NEOPLASMS, FEMALE; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0031128581     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4669     Document Type: Article

References (27)

1. Serrano M, Hannon G, Beach D A. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
2. Kamb A, Gruis N A, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian S V, Stockert E, Day R S III, Johnson B E, Skolnick M H. A cell cycle regulatory potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
3. Nobori T, Miura K, Wu D J, Lois A, Takabayashi K, Carson D A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 238:1994;753-756.
4. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of theMTS1/CDK4I. Cancer Res. 54:1994;3396-3397.
5. Spruck C H III, Gonzallez-Zullueta M, Shibata A, Simoneau A R, Lin M-F, Gozales F, Tsal Y C, Jones P A. p16. Nature. 370:1994;183-184.
6. Cheng J Q, Jhanwar S C, Klein W M, Bell D W, Lee W C, Altomare D A, Nobori T, Olopade O I, Bucker A J, Testa J R. p16. Cancer Res. 54:1994;5547-5551.
7. INK4Bis a potential effector of TGF-β-induced cell cycle arrest. Nature. 371:1994;257-261.
8. INK4/MTS1. Genes Der. 8:1994;2939-2943.
9. Je J, Harper J W, Bigner S H, Bigner D D, Padopoulos N, Markowitz S, Willson J KV, Kinzler K W, Vogerstein B. Deletion ofp16p15. Cancer Res. 54:1994;6353-6358.
10. INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 84:1994;4038-4042.
11. Hatta Y, Hirama T, Miller C W, Yamada Y, Tomonaga M, Koeffler H P. Homozygous deletions of the p15 (MTS2CDKN2/MTS1. Blood. 85:1995;2699-2704.
12. INK4B/MTS2,p18. Cancer Res. 55:1995;1448-1453.
13. Chenevix-Trench G, Kerr J, Friedlander M, Hurst T, Sanderson B, Goglan M, Ward B, Leary J, Khoo S K. Homozygous deletions on the short arm of chromosome in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am J Hum Genet. 55:1994;143-149.
14. Wang W, Wong Y F, Wong F WS, Chang A MZ. Chromosomal alterations in cervical carcinoma. Med Sci Res. 20:1992;193-194.
15. Wong Y F, Wang W, Wong F WS, Chang A MZ. Genetic studies in gynaecological malignancies. J Pract Gynecol Obstet. 9:1993;101-102.
16. Sambrook J, Fritch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
17. Cairns P, Mao A, Lee D J, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund J E, Sidransky D. Rates ofp16MTS1. Science. 265:1994;415-416.
18. Zhang S Y, Klein-Szanto A JP, Sauter E R, Shafarenko M, Mitsunaga S, Nobori T, Carson D A, Ridge J A, Goodrow T L. High frequency of alterations in thep16/CDKN2. Cancer Res. 54:1994;5050-5053.
19. ink4) in human breast carcinomas. Cancer Res. 54:1994;5262-5264.
20. INK4B/MTS2. Cancer Res. 55:1995;1436-1440.
21. Schultz D C, Vanderveer L, Buetow K H, Boente M P, Ozols R F, Hamilton T C, Godwin A K. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, includingCDKN2. Cancer Res. 55:1995;2150-2157.
22. Rodabaugh K J, Biggs R B, Quresh J A, Barrett A J, Welch W R, Bell D A, Berkowwitz R S, Mok S C. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene. 11:1995;1249-1254.
23. Knudson A G. Antioncogenes and human cancer. Proc Natl Acad Sci USA. 90:1993;10914-10921.
24. Moulton T, Samara G, Chung W-Y, Yuan L, Desai R, Sisti M, Bruce J, Tycko B. MTS1/p16/CDKN2 lesions in primary glioblastoma multiform. Am J Pathol. 146:1995;613-619.
25. Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressorp16/CDKN2/MTS1. Nat Med. 1:1995;686-692.
26. Herman J G, Merlo A, Mao L, Lapidus R G, Issa J J, Davidson N E, Sidransky D, Baylin S B. Inactivation ofCDKN2/p16/MTS1. Cancer Res. 55:1995;4525-4530.
27. He J, Allen J R, Collins V P, Allalunis-Turner M J, Godbout R, Day R S III, James C D. CDK4 amplification is an alternative mechanism top16. Cancer Res. 54:1994;5804-5807.